- cafead Feb 08, 2022 at 10:32: AM
via A new biotech aiming to tackle protein misfolding has landed a substantial Series A from some blue-chip investors.
Congruence Therapeutics burst onto the scene Tuesday with a $50 million round, including funds from OrbiMed. The biotech will use the money to advance its platform and move some of its programs forward, CEO Clarissa Desjardins told Endpoints News.
article source
Congruence Therapeutics burst onto the scene Tuesday with a $50 million round, including funds from OrbiMed. The biotech will use the money to advance its platform and move some of its programs forward, CEO Clarissa Desjardins told Endpoints News.
article source